Search Result

Results for "

insulin+sensitization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ABA Receptor (2) Acyltransferase (1) Adenosine Receptor (1) Akt (1) Amine N-methyltransferase (1) Amylin Receptor (1) Apoptosis (1) Calcium Channel (1) CGRP Receptor (3) Endogenous Metabolite (4) Environmental Pollutants (1) ERK (1) Fatty Acid Synthase (FASN) (1) Insulin Receptor (9) Interleukin Related (1) Lactate Dehydrogenase (1) Lipase (1) Mitochondrial Metabolism (2) NOD-like Receptor (NLR) (4) Phosphatase (2) Phosphodiesterase (PDE) (1) PPAR (7) Proton Pump (2) RAR/RXR (2) Reference Standards (3) SHP2 (1) TRP Channel (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Endocrinology (4) Inflammation/Immunology (8) Metabolic Disease (22) Neurological Disease (5)

By Targets:

ABA Receptor (2)

Acyltransferase (1)

Adenosine Receptor (1)

Akt (1)

Amine N-methyltransferase (1)

Amylin Receptor (1)

Apoptosis (1)

Calcium Channel (1)

CGRP Receptor (3)

Endogenous Metabolite (4)

Environmental Pollutants (1)

ERK (1)

Fatty Acid Synthase (FASN) (1)

Insulin Receptor (9)

Interleukin Related (1)

Lactate Dehydrogenase (1)

Lipase (1)

Mitochondrial Metabolism (2)

NOD-like Receptor (NLR) (4)

Phosphatase (2)

Phosphodiesterase (PDE) (1)

PPAR (7)

Proton Pump (2)

RAR/RXR (2)

Reference Standards (3)

SHP2 (1)

TRP Channel (2)

By Research Areas:

Cancer (8)

Cardiovascular Disease (1)

Endocrinology (4)

Inflammation/Immunology (8)

Metabolic Disease (22)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100560

Abscisic acid 3 Publications Verification (S)-(+)-Abscisic acid; ABA	Environmental Pollutants Endogenous Metabolite ABA Receptor Proton Pump	Metabolic Disease
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H ⁺-ATPase) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-101064

Fmoc-leucine N-FMOC-leucine; NPC 15199; NSC 334290	PPAR Calcium Channel Lipase	Metabolic Disease Inflammation/Immunology
Fmoc-Leucine (N-FMOC-leucine) is an anti-inflammatory agent that not only promotes extracellular Ca ²⁺ influx but also facilitates intracellular Ca ²⁺ release. Fmoc-Leucine is a selective ligand for PPARγ (K_i = 15 μM), exhibiting insulin-sensitizing effects but with weak fatogenic activity. Fmoc-Leucine exhibits unique self-assembly properties and can form transient gels, stable gels, or crystals/2D sheets through different pathways. Fmoc-Leucine can be used in the research of diabetes, colitis, and bladder cancer .

HY-13682

Mifamurtide 5 Publications Verification MTP-PE; L-MTP-PE; CGP 19835	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research .

HY-19960

BCTC 5 Publications Verification	TRP Channel Insulin Receptor CGRP Receptor	Neurological Disease Metabolic Disease Cancer
BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects .

HY-112584

JBSNF-000088 Maximum Cited Publications 9 Publications Verification 6-Methoxynicotinamide	Amine N-methyltransferase	Metabolic Disease
JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC₅₀s of 1.8 µM, 2.8 µM, and 5.0 µM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease .

HY-100550

MSDC 0160 4 Publications Verification Mitoglitazone; CAY10415	Insulin Receptor Mitochondrial Metabolism	Neurological Disease Endocrinology
MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating *insulin sensitizer* and a modulator of mitochondrial pyruvate carrier (MPC). MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease .

HY-118567

Bis(maltolato)oxovanadium(IV) BMOV	SHP2 Phosphatase	Metabolic Disease
Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC₅₀s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer .

HY-108022A

Azemiglitazone potassium 1 Publications Verification MSDC-0602K	Insulin Receptor PPAR	Metabolic Disease
Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC₅₀ of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an *insulin* sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-100560R

Abscisic acid (Standard) (S)-(+)-Abscisic acid (Standard); ABA (Standard)	Reference Standards Endogenous Metabolite Proton Pump ABA Receptor	Metabolic Disease
Abscisic acid (Standard) is the analytical standard of Abscisic acid. This product is intended for research and analytical applications. Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-108523

LG100754 UVI 2112	RAR/RXR	Metabolic Disease
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .

HY-N0597

Panaxatriol 3 Publications Verification	Others Insulin Receptor	Cardiovascular Disease Others Metabolic Disease Cancer
Panaxatriol is an orally active insulin sensitizer. Panaxatriol enhances the phosphorylation levels of Akt, insulin receptor and p70S6K in skeletal muscle. Panaxatriol reduces the mRNA expression level of Atrogin1 in skeletal muscle. Panaxatriol induces apoptosis, pre-G1 cell cycle arrest and increased intracellular ROS levels in prostate cancer cells, decreases mitochondrial membrane potential, inhibits cell migration and reduces colony formation. Panaxatriol can be used in research related to insulin resistance, myocardial ischemia/reperfusion injury and prostate cancer .

HY-N2177

3-Dehydrotrametenolic acid	Lactate Dehydrogenase Apoptosis	Cancer
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity .

HY-13682B

Mifamurtide sodium 5 Publications Verification MTP-PE sodium; L-MTP-PE sodium; CGP 19835 sodium	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide sodium has potential for use in rare disease and osteosarcoma research .

HY-13682C

Mifamurtide TFA 5 Publications Verification MTP-PE TFA; L-MTP-PE TFA; CGP 19835 TFA	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide TFA (MTP-PE TFA), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide TFA is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide TFA has potential for use in rare disease and osteosarcoma research .

HY-121900

LT175	PPAR	Metabolic Disease Endocrinology
LT175, a dual PPARα/γ ligand, is an orally active partial agonist against PPARγ(hPPARα:EC₅₀=0.22 μm; mPPARα:EC₅₀=0.26 μm; hPPARγ:EC₅₀=0.48 μm). LT175 interacts with PPARγ and affects the recruitment of the coregulators cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1). LT175 interacts with PPARγ in a hydrophobic region called “diphenyl pocket”. LT175 has potent insulin-sensitizing effects and reduced adipogenic properties .

HY-164368

GLUT4 activator 2	Phosphodiesterase (PDE) Insulin Receptor	Metabolic Disease
GLUT4 activator 2 (C59) is an *insulin* sensitizer, which can be used for research of diabetic diseases. GLUT4 activator 2 improves glucose uptake and insulin sensitivity in rodents. GLUT4 activator 2 interacts with Unc119 and Unc119B resulting in increased insulin sensitivity and GLUT4 translocation .

HY-178958

PPAR agonist 7	PPAR Adenosine Receptor Fatty Acid Synthase (FASN) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC₅₀ = 1.51 μM), PPARδ (EC₅₀ = 1.11 μM), and PPARγ (EC₅₀ = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/ Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes .

HY-13682A

Mifamurtide sodium hydrate MTP-PE sodium hydrate; L-MTP-PE sodium hydrate; CGP 19835 sodium hydrate	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide (MTP-PE; CGP 19835) sodium hydrate is the sodium hydrate of mifamurtide. Mifamurtide is a nonspecific immunomodulator that acts by stimulating immune responses by activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and is used as an insulin sensitizer and may also be used in osteosarcoma research .

HY-19176

S-15261	Insulin Receptor	Metabolic Disease
S-15261 is an orally active and potent anti-hyperglycemic agent. S-15261 reduces hepatic glucose production through direct and insulin-sensitizing effects. S-15261 can be used for the research of insulin resistance syndrome .

HY-126969

C333H	PPAR	Metabolic Disease
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .

HY-113655

AD-5075	PPAR	Metabolic Disease
AD-5075 is an orally active insulin sensitizer. AD-5075 mediates its antidiabetic activity by binding to PPARγ and thereby generating an active conformation of the receptor .

HY-138842

DDN	Insulin Receptor Akt ERK	Metabolic Disease
DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .

HY-19960R

BCTC (Standard)	TRP Channel Insulin Receptor CGRP Receptor	Neurological Disease Metabolic Disease Cancer
BCTC (Standard) is the analytical standard of BCTC. This product is intended for research and analytical applications. BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects .

HY-P11629

KBP-336	Amylin Receptor CGRP Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .

HY-118523

AL-321	Endogenous Metabolite	Metabolic Disease
AL-321 is an insulin sensitizer. AL-321 exhibits significant hypoglycemic and hypolipidemic activities in insulin resistance models. AL-321 can be used in the research of hereditary obesity-related diabetes .

HY-108523R

LG100754 (Standard) UVI 2112 (Standard)	Reference Standards RAR/RXR	Metabolic Disease
LG100754 (Standard) is the analytical standard of LG100754 (HY-108523). This product is intended for research and analytical applications. LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .

HY-100550R

MSDC 0160 (Standard) Mitoglitazone (Standard); CAY10415 (Standard)	Insulin Receptor Reference Standards Mitochondrial Metabolism	Neurological Disease Endocrinology
MSDC 0160 (Standard) is the analytical standard of MSDC 0160 (HY-100550). This product is intended for research and analytical applications. MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC). MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease .

HY-N17326

Ilekudinol B	Acyltransferase Phosphatase Interleukin Related	Metabolic Disease Inflammation/Immunology
Ilekudinol B is an inhibitor of ACAT and PTP1B, with an IC₅₀ of 5.3 μM and a K_i of 11.6 μM against human PTP1B. Ilekudinol B inhibits the classical pathway of the complement system, with an IC₅₀ of 51 μM. Ilekudinol B inhibits TNF-α-induced cellular IL-8 secretion, promotes glucose uptake in skeletal muscle myotubes, and acts as an insulin mimetic and insulin sensitizer. Ilekudinol B can be used in research related to type 2 diabetes, obesity, and inflammatory diseases .

Cat. No.	Product Name	Target	Research Area

HY-P11629

KBP-336	Amylin Receptor CGRP Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .

Abscisic acid 3 Publications Verification (S)-(+)-Abscisic acid; ABA	Structural Classification Classification of Application Fields Metabolic Disease Plants Endogenous metabolite Agricultural Research Microorganisms other families Animals Terpenoids Sesquiterpenes Abscisic acid Phytohormone Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite ABA Receptor Proton Pump
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H ⁺-ATPase) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

Abscisic acid (Standard) (S)-(+)-Abscisic acid (Standard); ABA (Standard)	Structural Classification Microorganisms other families Animals Terpenoids Sesquiterpenes Plants Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Proton Pump ABA Receptor
Abscisic acid (Standard) is the analytical standard of Abscisic acid. This product is intended for research and analytical applications. Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

Panaxatriol 3 Publications Verification	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	Others Insulin Receptor
Panaxatriol is an orally active insulin sensitizer. Panaxatriol enhances the phosphorylation levels of Akt, insulin receptor and p70S6K in skeletal muscle. Panaxatriol reduces the mRNA expression level of Atrogin1 in skeletal muscle. Panaxatriol induces apoptosis, pre-G1 cell cycle arrest and increased intracellular ROS levels in prostate cancer cells, decreases mitochondrial membrane potential, inhibits cell migration and reduces colony formation. Panaxatriol can be used in research related to insulin resistance, myocardial ischemia/reperfusion injury and prostate cancer .

3-Dehydrotrametenolic acid	Triterpenes Classification of Application Fields Terpenoids Polyporaceae Poria cocos Plants Disease Research Fields Source Classification Cancer	Lactate Dehydrogenase Apoptosis
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity .

Ilekudinol B	Weigela subsessilis (Nakai) L.H.Bailey Structural Classification Caprifoliaceae Terpenoids Plants Pentacyclic Triterpenoids Source Classification	Acyltransferase Phosphatase Interleukin Related
Ilekudinol B is an inhibitor of ACAT and PTP1B, with an IC₅₀ of 5.3 μM and a K_i of 11.6 μM against human PTP1B. Ilekudinol B inhibits the classical pathway of the complement system, with an IC₅₀ of 51 μM. Ilekudinol B inhibits TNF-α-induced cellular IL-8 secretion, promotes glucose uptake in skeletal muscle myotubes, and acts as an insulin mimetic and insulin sensitizer. Ilekudinol B can be used in research related to type 2 diabetes, obesity, and inflammatory diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks